SD HEALTHCARE
Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Dexcom Delivers With Impressive Q3 Results
Company Looking At Various Avenues to Expand Its MarketIn what an analyst called another blowout quarter, Dexcom on Nov. 6 posted $396.3 million in third quarter revenue, a 49% year-over-year increase.LifeNet Health Acquires Organovo Subsidiary
LifeNet Health has acquired Samsara Sciences, a subsidiary of Organovo that provides human liver cells for drug research.
Currax Buys Nalpropion, Gains Weight-Loss Drug
New Jersey’s Currax Pharmaceuticals now holds the rights to contrave, a weight-loss drug with San Diego roots.
After Missing Mark in Clinical Trials, Halozyme Focuses on Delivery Platform
BIOTECH: Cancer Drug Failed to Extend Patient Lives
For many biotechs, the news would be a death knell.
The Ups and Downs Of Third Quarter Life Sciences Leasing
PROPERTY: Mirati Leads the 20 Deals Made With 64,108 Square Feet
More life sciences companies took space in the third quarter, but industry leasing activity still fell compared with the same period a year ago.
Neurocrine Reports 46% Spike in Revenue for Q3
PHARMA: Company Positioning Itself to Be a Leading Global Biopharma Organization
Neurocrine Biosciences reported revenue of $222.09 million in third quarter results.
Grants Give Researchers Tools To Tackle Problems
Oceanographers Team Up to Examine Toxic Algae Blooms
Toxic algae blooms. Injuries from nerve damage. Brain disorders- these are problems San Diego researchers hope to better understand.
Tandem Diabetes Care Reports Jump in Q3 Sales
Tandem Diabetes Care logged a jump in third quarter revenue as the company moved toward profitability.
Gut Health Is Goal Of Sun Genomics’ Custom Probiotics
Targeted Solutions Said To Take Complexity of Microbiome Into Account
A crop of companies take a person’s fecal sample and profile the microbiome, living microorganisms in the digestive system that are getting increased attention.
Heron Candidate Could Be Pain Med Alternative to Opioids
Analyst Sees Potential As Blockbuster Treating Postoperative Pain
In April, the U.S. Food and Drug Administration kicked back an application from Heron Therapeutics asking for approval of its experimental pain medicine.
Intrepida Bio Launches with $9.5M
Intrepida Bio seeks to modulate the immune system to fight cancer and other diseases.
Neurocrine Reports 46% Spike in Revenue
Neurocrine reported revenue of $222.09 million in third quarter results, a 46.3% year-over-year jump.
Freeze in Joining Association Health Plans Hits Small Companies
INSURANCE: State Action Aims to Support ACA Pool
California companies with fewer than 100 employees were recently barred from joining associations related to their industry to get better insurance rates.
Qpex Biopharma and Brii Biosciences Partner to Take on Superbugs
San Diego’s Qpex Biopharma has licensed three of its programs for drug-resistant bacterial infections to a firm with a mission of bringing breakthrough treatments to China.
Illumina Reports 6% Increase In Q3 Revenue
GENOMICS: Next Big Growth Driver May Be Initiatives By Governments
Illumina Inc. reported $907 million in third quarter revenue, a 6% year-over-year increase that beat Wall Street expectations.
Prev Next